Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5464368 | 0.85 | HRH3 (0.50) | HRH3CYP2D6DRD3HTR6L3MBTL1 | |
| SCHEMBL5464883 | 0.84 | HRH3 (0.51) | HRH3CYP2D6POLBHRH1L3MBTL3 | |
| SCHEMBL5460076 | 0.82 | POLB (0.57) | HRH3CYP2D6POLBRIPK1HRH1 | |
| SCHEMBL5672950 | 0.79 | L3MBTL3 (0.57) | HRH3POLBDRD3HTR6L3MBTL3 | |
| SCHEMBL5458191 | 0.77 | HRH3 (0.58) | HRH3CYP2D6L3MBTL3L3MBTL1 | |
| SCHEMBL5465815 | 0.77 | HPGD (0.52) | HRH3CYP2D6L3MBTL3L3MBTL1 | |
| SCHEMBL5470100 | 0.77 | L3MBTL1 (0.58) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL14441056 | 0.77 | HRH3 (0.58) | HRH3CYP2D6L3MBTL3L3MBTL1 | |
| SCHEMBL4767427 | 0.76 | HRH3 (0.50) | HRH3HRH1 | |
| SCHEMBL5459682 | 0.76 | HRH3 (0.52) | HRH3CYP2D6TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185089-A1 | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | CNR2, GRIN2C, GRIN2B | HRH3 38/4885CYP2D6 425/4885TLR9 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.